The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | DPd against DVd for daratumumab-naïve patients with R/R multiple myeloma
Hamza Hashmi, MD, Medical University of South Carolina, Charleston, SC, provides insight into the findings of a study comparing the safety and efficacy of daratumumab, pomalidomide and dexamethasone (DPd) against daratumumab, bortezomib, and dexamethasone (DVd) in previously treated daratumumab-naïve patients with relapsed/refractory (R/R) multiple myeloma. While the study did not show any statistically significant differences in response rates (RR), progression-free survival (PFS), and overall survival (OS), patients treated with DPd experienced more cytopenias whereas patients treated with DVd had a higher risk of developing peripheral neuropathy. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Speakers Bureau; GSK: Speakers Bureau; KARYOPHARM: Speakers Bureau; JANSSEN: Consultancy; BMS: Consultancy.
